AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology
company focused on the development and commercialization of novel
bacteriophage-based antibacterial therapeutics, today announced topline
results from its Phase 1 trial to evaluate the safety and tolerability
of AB-SA01, its proprietary investigational phage cocktail targeting Staphylococcus
aureus (S. aureus) infections in patients suffering from
chronic rhinosinusitis (CRS). Enrollment in the trial has been completed
and the Safety Monitoring Committee overseeing the trial has determined
that AB-SA01 was well-tolerated by all nine patients and that there were
no drug-related serious adverse events.

“We believe that completing enrollment of our two Phase 1 clinical
trials of AB-SA01 in 2016 and the favorable topline results we've seen
from them will pave the way for AmpliPhi to initiate Phase 2 clinical
trials in 2017,” said M. Scott Salka, CEO of AmpliPhi Biosciences.
“Controlled efficacy studies of phage therapy have yet to be conducted
under modern regulatory requirements, making these pioneering studies
potentially significant milestones not just for AmpliPhi, but for the
entire emerging field of phage therapy. I would like to thank the entire
AmpliPhi team as well as our partners for their contributions toward
meeting theses important goals that bring us closer to our mission of
delivering better treatment to patients suffering from chronic
infections. We look forward to reporting complete study results later
this year.”

The Phase 1 clinical trial in CRS patients was initiated in January 2016
and was conducted at the Queen Elizabeth Hospital in collaboration with
the University of Adelaide and Flinders University. Nine patients were
enrolled in the trial and received AB-SA01 in one of three different
dose regimens: Cohort 1—low dose, twice daily for seven days; Cohort
2—low dose, twice daily for 14 days; and, Cohort 3—high dose, twice
daily for 14 days. AmpliPhi expects to report complete trial results by
the end of 2016.

About AmpliPhi Biosciences

AmpliPhi Biosciences Corporation (NYSEMKT: APHB) is a biotechnology
company focused on the development and commercialization of novel
bacteriophage-based antibacterial therapeutics. AmpliPhi's product
development programs target infections that are often resistant to
existing antibiotic treatments. AmpliPhi has reported topline results
from two Phase 1 clinical trials of AB-SA01, one for the treatment of S.
aureus in chronic rhinosinusitis patients and one to evaluate
the safety of AB-SA01 when administered topically to the intact skin of
healthy adults. AmpliPhi expects to report final data from each trial by
the end of 2016. AmpliPhi is also developing bacteriophage therapeutics
targeting Pseudomonas aeruginosa (P. aeruginosa) and Clostridium
difficile (C. difficile) in collaboration with a number
of leading organizations focused on the advancement of
bacteriophage-based therapies.

About Bacteriophage

Bacteriophage are naturally-occurring viruses that are highly specific
for the bacterial hosts they infect. They can rapidly kill their host,
producing hundreds of offspring viruses in the process. Bacteriophage
are unaffected by antibiotic resistance and are able to disrupt
bacterial biofilms, which are a major line of defense for bacteria and
help them resist antibiotics. Bacteriophage can effectively penetrate
biofilms to produce strong local therapeutic effects without destroying
bacteria important to normal human health.

Forward Looking Statements

Statements in this press release that are not statements of historical
fact are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements include, without limitation, statements about the expected
timing of reporting final data from AmpliPhi’s two AB-SA01 trials, the
expected timing of initiating Phase 2 clinical trials, the potential use
of bacteriophages to treat bacterial infections, including infections
that do not respond to antibiotics, the potential benefits of phage
therapy, and AmpliPhi’s development of bacteriophage-based therapies.
Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,”
“will,” “may,” “goal,” “potential” and similar expressions are intended
to identify forward-looking statements, though not all forward-looking
statements necessarily contain these identifying words. These
forward-looking statements are based upon AmpliPhi’s current
expectations and involve a number of risks and uncertainties, including
the risks and uncertainties described in AmpliPhi’s Quarterly Report on
Form 10-Q for the quarter ended June 30, 2016, as filed with the
Securities and Exchange Commission. Actual results and the timing of
events could differ materially from those anticipated in such
forward-looking statements as a result of these risks and uncertainties.
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. All
forward-looking statements are qualified in their entirety by this
cautionary statement, and AmpliPhi undertakes no obligation to revise or
update any forward-looking statements to reflect events or circumstances
after the date of this press release.

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.